Last reviewed · How we verify
valsartan/amlodipine
Valsartan blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload.
Valsartan blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload. Used for Hypertension, Hypertension in patients not adequately controlled on monotherapy.
At a glance
| Generic name | valsartan/amlodipine |
|---|---|
| Also known as | Exforge® |
| Sponsor | Novartis |
| Drug class | Angiotensin II receptor blocker / Calcium channel blocker combination |
| Target | AT1 receptor / L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This is a fixed-dose combination of two antihypertensive agents with complementary mechanisms. Valsartan is an angiotensin II receptor blocker (ARB) that prevents vasoconstriction and aldosterone release, reducing blood pressure and cardiac strain. Amlodipine is a dihydropyridine calcium channel blocker that causes vasodilation by inhibiting calcium influx into vascular smooth muscle cells. Together, they provide synergistic blood pressure reduction.
Approved indications
- Hypertension
- Hypertension in patients not adequately controlled on monotherapy
Common side effects
- Peripheral edema
- Dizziness
- Fatigue
- Headache
- Hyperkalemia
- Cough
Key clinical trials
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- Integration of Hypertension Management in HIV Care in Uganda (NA)
- Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy (PHASE3)
- Comparing Bisoprolol and Valsartan-Amlodipine for Hypertension (PHASE4)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity (PHASE4)
- A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension (PHASE3)
- The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- valsartan/amlodipine CI brief — competitive landscape report
- valsartan/amlodipine updates RSS · CI watch RSS
- Novartis portfolio CI